Drug intelligence / Profile preview

CC-99282 + tafasitamab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

CC-99282 + tafasitamab is an investigational combination therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, notably including diffuse large B-cell lymphoma (DLBCL) and potentially follicular lymphoma. CC-99282 is an oral immunomodulatory agent in the class of cereblon E3 ligase modulators (CELMoDs); tafasitamab (Monjuvi) is a monoclonal antibody targeting CD19 on B cells. CC-99282 enhances immune response against lymphoma cells, while tafasitamab binds CD19 to promote immune-mediated cytotoxicity and phagocytosis. The combination is being studied for increased anti-tumor efficacy through dual immunomodulation and B-cell targeting, with clinical trials in relapsed/refractory DLBCL and B-cell non-Hodgkin lymphoma[2][4].

Brand names: Monjuvi
Other names: tafasitamab-cxix

Targets

CD19 (B lymphocyte antigen CD19)CRBN (Cereblon)

Beyond the preview

Go deeper on CC-99282 + tafasitamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-99282 + tafasitamab.

Explore the full profile